PDS Biotechnology Corp
PDSB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PDSB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PDSB
PDS Biotechnology Corp (PDSB) is a clinical-stage biopharmaceutical company developing immunotherapies for cancer and infectious diseases, currently prioritizing its PDS0301 candidate after discontinuing a Phase 3 trial of PDS0101.
Key risk: Going concern uncertainty
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 2 clinical trials · 1 catalyst for PDS Biotechnology Corp.
Similar companies
PDS Biotechnology Corp (PDSB) is a clinical-stage biopharmaceutical company developing immunotherapies for cancer and infectious diseases, currently prioritizing its PDS0301 candidate after discontinuing a Phase 3 trial of PDS0101.
- As of June 30, 2026, PDS Biotechnology had $5.6 million in cash and cash equivalents and an accumulated deficit of $233.7 million [sec_mda · as of 2026-08-13].
- The company has concluded that substantial doubt exists about its ability to continue as a going concern [sec_mda · as of 2026-08-13].
- PDS Biotechnology recently discontinued the VERSATILE-003 Phase 3 clinical trial of PDS0101 and strategically refocused on developing PDS0301 [sec_mda · as of 2026-08-13].
- The company has not generated any product revenue to date and expects to continue incurring losses as it advances its product candidates [sec_mda · as of 2026-05-14].
What works
- PDS Biotechnology is advancing PDS0301, a mid-clinical-stage immunotherapy candidate, which may address unmet medical needs if successfully developed and approved [sec_mda · as of 2026-08-13].
- The company holds intellectual property rights related to its Versamune® and Infectimune® platforms, which could provide competitive advantages if products are commercialized [sec_mda · as of 2026-08-13].
What to weigh
- PDS Biotechnology has a going concern risk, with only $5.6 million in cash as of June 30, 2026, and a history of significant operating losses [sec_mda · as of 2026-08-13].
- The discontinuation of the VERSATILE-003 Phase 3 trial may increase investor uncertainty and make it more difficult to obtain financing on acceptable terms [sec_mda · as of 2026-08-13].
- The company is dependent on raising additional capital to fund its planned Phase 2b clinical trial for PDS0301 and maintain operations, with no assurance of securing such financing [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Going concern risk due to low cash balance
“As of June 30, 2026, we had $5.6 million in cash and cash equivalents, and we have concluded that substantial doubt exists about our ability to continue as a going concern.”
SEC MD&A · August 13, 2026
Strategic refocus from PDS0101 to PDS0301
“the Company's recent strategic refocus to prioritize the development of PDS0301 and to discontinue the VERSATILE-003 Phase 3 clinical trial of PDS0101 may not achieve the anticipated benefits and involves significant risks and uncertainties;”
SEC MD&A · August 13, 2026
Accumulated deficit and no product revenue
“As of June 30, 2026, we had an accumulated deficit of $233.7 million.”
SEC MD&A · August 13, 2026
Dependence on external financing
“Our ability to advance PDS0301 through its planned Phase 2b clinical trial and to maintain operations is dependent upon our ability to raise additional capital.”
SEC MD&A · August 13, 2026
Catalyst timeline
- 2029-02-01 · Phase3_Topline · pds0101 — Phase 3 Topline: A Phase 3 Open-Label, Randomized Study of PDS0101 and Pembrolizumab vs Pembrolizumab Alone in First- — Topline data from the Phase 3 trial of PDS0101 in combination with pembrolizumab is expected, though the trial has been discontinued; the catalyst date may be subject to change.
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern due to low cash reserves [sec_mda · as of 2026-08-13].
- Dependence on financing — Requires additional capital to fund PDS0301 Phase 2b trial and operations; no assurance of availability [sec_mda · as of 2026-08-13].
- Clinical and regulatory risk — PDS0301 is in mid-clinical development; may not obtain regulatory approval or be commercialized [sec_mda · as of 2026-08-13].
- No product revenue — Company has not generated any product revenue and expects continued losses [sec_mda · as of 2026-05-14].
What to watch
- Initiation and progress of the planned Phase 2b clinical trial for PDS0301 [sec_mda · as of 2026-08-13].
- Ability to raise additional capital through equity, debt, or strategic partnerships to fund operations [sec_mda · as of 2026-08-13].
- Potential impact of the discontinued VERSATILE-003 trial on investor sentiment and financing prospects [sec_mda · as of 2026-08-13].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run PDS Biotechnology Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PDS Biotechnology Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
6.5 months
OCF -$3M · Net income -$10M
Lead: Phase 3
5 candidates
1 upcoming, next in ~886d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
41
Total value held
$4.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 3,262,178 | $2.0M |
| geode capital management, llc | 660,228 | $399K |
| blackrock, inc. | 554,048 | $335K |
| caption management, llc | 319,100 | $193K |
| vanguard fiduciary trust co | 307,311 | $186K |
| renaissance technologies llc | 220,800 | $134K |
| inspirion wealth advisors, llc | 181,995 | $110K |
| armistice capital, llc | 173,605 | $105K |
| state street corp | 133,333 | $81K |
| wells fargo & company/mn | 110,500 | $67K |
Showing top 10 of 41 institutional holders of PDS Biotechnology Corp. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 3.2%
- Days to cover
- 1.4
- Shares short
- 1,705,936
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PDSB short interestGovernance
Frequently asked questions
What is the AI investment thesis for PDS Biotechnology Corp?
PDS Biotechnology Corp (PDSB) is a clinical-stage biopharmaceutical company developing immunotherapies for cancer and infectious diseases, currently prioritizing its PDS0301 candidate after discontinuing a Phase 3 trial of PDS0101.
What is PDS Biotechnology Corp's next catalyst?
PDS Biotechnology Corp's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Open-Label, Randomized Study of PDS0101 and Pembrolizumab vs Pembrolizumab Alone in First-" — expected February 1, 2029.
Who is the CEO of PDS Biotechnology Corp?
Dr. Frank K. Bedu-Addo Ph.D. is the chief executive officer of PDS Biotechnology Corp (PDSB).
Where is PDS Biotechnology Corp headquartered?
PDS Biotechnology Corp (PDSB) is headquartered in Princeton, NJ, United States.
What therapeutic areas does PDS Biotechnology Corp focus on?
PDS Biotechnology Corp develops therapies across Oncology, Immunology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.